Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
Primary Industries
- Drugs
- Vaccine
- Cancer
- Delivery
- DNA
- Therapeutic
- Disease
- HIV / AIDs
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 204336
License Grant
Licensor grants a non-exclusive, worldwide, non-transferable license, with the right to sublicense, under the Patent Rights to develop, make, have made, use, offer for sale, sell, have sold and import the Products designated solely for use in the Field and to use the Biological Material for such purposes.
License Property
The Product means a DNA construct comprised of combinations of epitopes derived from a combination of a unique number and type of tumor-associated antigens and developed by Licensee.
The patents relate to Formulated Nucleic Acid Compositions and Methods of Administering the Same for Gene Therapy.
Field of Use
The field shall mean the prophylactic and/or therapeutic treatment of cancer in humans using plasmid-based vaccines.
IPSCIO Record ID: 249713
License Grant
Licensor grants to Licensee of the United Kingdom a non-exclusive license under Technology to develop, have developed, make, have made, use, have used, sell, offer for sale, have sold, keep and/or import in the Territory and in the Field any Products and/or Combinations in any formulation, composition or delivery systems which contain any of the following two Licensed Antigens
• Any and all ANTIGENS expressed in Prostate Cancer
• Any and all ANTIGENS expressed in Breast Cancer.
In further consideration of the obligations assumed by Licensee and subject to the terms and conditions of this Agreement, as of May 22, 2002 Licensee grants a non-exclusive license under Technology to develop, have developed, make, have made, use, have used, sell, offer for sale, have sold, keep and/or import in the Territory and in the Field any Products and/or Combinations in any formulation, composition or delivery systems which contain the following Licensed Antigens
• Any and all Antigens expressed in Lung Cancer
License Property
The Product shall mean any and all pharmaceutical compositions for Prophylactic Immunization and/or Therapeutic Immunization in the field comprising one or more of the Licensed Antigens in combination with Adjuvant as an ingredient or component in any formulation, configuration, combination and/or delivery system, in which Adjuvant induces, augments, fine-tunes or enhances the Antigen specific immune response of any of such Licensed Antigens contained within Product.
The patents relate to Nucleic Acid and lmmunostimulatory methods and processes.
Field of Use
The Field shall mean the use of Adjuvant in combination with Licensed Antigens as part of a Product and/or Combination for the purpose of inducing, augmenting, fine-tuning or enhancing in vivo, in vitro or ex vivo of an Antigen specific immune response and in all cases for Prophylactic Immunization and/or Therapeutic Immunization against Licensed Cancers in humans, excluding Specific Field.
Specific Field shall mean without limitation the use of Adjuvant in combination with DNA Vaccines or other than in combination with a Licensed Antigen and independently from a Licensed Antigen or in combination with antibodies in passive immunotherapy applications when not combined with a tumor Antigen; or in all non Antigen specific ex vivo applications or for all purposes other than eliciting, inducing, augmenting, fine-tuning or enhancing an Antigen-specific immune response.
IPSCIO Record ID: 368651
License Grant
Licensor grants a worldwide, exclusive license to Licensor Patent Rights and Know-How to make, have made, use, import, offer to sell, and sell Product using Licensed Compound supplied by Licensor, or supplied by a third party, for use in the Field.
This agreement includes a non-exclusive grant back from Licensee to Licensor.
License Property
Licensor, through its Drug Delivery Systems Division, has expertise and technology, with know-how and patents owned by Licensor, relating to toll-like receptor TLR 7 and/or 8 immune response modifier (IRM) compounds, formulations, conjugation, delivery, and manufacturing including proprietary IRM compounds such as resiquimod and others, that are useful as vaccine adjuvants.
The Compound is designated by Licensor as Resiquimod (R-848), S36212, 1-(4-aminobutoxy) -2-butyl-lH-imidazo (4,5-cl quinolin-4-amine and conjugates thereof.
Product shall mean any combination of a Licensee Antigen Presenting Cell or APC Targeting Technology vaccine with a Licensed Compound to be utilized as a Vaccine Adjuvant.
Vaccine Adjuvant shall mean a Licensed Compound which is used to induce, augment, fine-tune, enhance, or desensitize an antigen-specific immune response to an antigen contained in a vaccine or generated by a DNA vaccine for the therapeutic treatment of an existing disease or prophylactic use as protection against future disease, including desensitization to allergens. The antigen and the vaccine adjuvant may be admixed, delivered simultaneously, conjugated, or delivered separately, provided however, that the separate administration of the antigen and vaccine adjuvant is limited to the topical, dermal or mucosal or intradermal routes of administration and must be administered within 48 hours at substantially the same site and labeled as such by the applicable regulatory authority.
TLR compounds, also called TLR7 and TLR8 agonists, are small organically synthesized molecules that offer flexibility in formulating and route of delivery, and ease in manufacturing, unlike most other TLR agonists, which are much larger and not as easy to manufacture.
Field of Use
Licensor’s patented TLR immune response modifier compounds, which may be useful as vaccine adjuvants, will be used by Licensee to develop new vaccine products. This license agreement provides a great opportunity to combine synergistic technologies designed to treat various cancers and infectious diseases.
The Field shall mean human prophylactic or therapeutic vaccination against any and all cancer disease states and selected infectious diseases.
This agreement focus is Cancer and the Infectious Diseases
– human immunodeficiency virus (HIV);
– human papillomavirus (HPV); and,
– hepatitis B virus (HBV).
IPSCIO Record ID: 249711
License Grant
Licensor grants a co-exclusive license, except non-exclusive license for HIV, in accordance with the terms stated herein.
Licensor grants to the United Kingdom Licensee and to any affiliates the following licenses, with the right to grant sublicenses, under Technology to develop, have developed, make, have made, use, have used, sell, offer for sale, have sold, keep and/or import in the Territory and in the Field all Products and/or Combinations, subject to the following
– For Prophylactic Immunization within the Field, Licensor grants a Co-exclusive license for the following Licensed Antigens, including combinations thereof, and no other Antigens
• HPV ANTIGENS
• HBV ANTIGENS
• INFLUENZA ANTIGENS
• Chlamydia ANTIGENS
• Mycobacterium ANTIGENS
• RSV ANTIGENS
• Malaria ANTIGENS
– For Prophylactic Immunization within the Field, Licensor grants a non-exclusive license for the following Licensed Antigens and no other Antigens
• HIV ANTIGENS
– For Therapeutic immunization within the Field Licensor grants a co-exclusive license for the following Licensed Antigens, including combinations thereof, and no other Antigens
• HPV ANTIGENS
• HBV ANTIGENS
• Chlamydia ANTIGENS
• Mycobacterium ANTIGENS
License Property
The Product shall mean any and all pharmaceutical compositions for the Prophylactic Immunization and/or Therapeutic Immunization against infectious diseases in humans comprising one or more of the Licensed Antigens in combination with Adjuvant as an ingredient or component in any formulation, configuration, combination and/or delivery system, to the extent Adjuvant induces, augments, fine-tunes or enhances the Antigen specific immune response of such Licensed Antigens contained within Product.
The patents relate to the use of Nucleic Acid.
Field of Use
The field shall mean the use of Adjuvant in combination with Licensed Antigens as part of a Product and/or Combination for Prophylactic Immunization and/or Therapeutic Immunization against infectious diseases in humans, expressly excluding the Specific Field.
Specific Field shall mean the use of Adjuvant as part of or in conjunction with a DNA Vaccine or other than in combination with a Licensed Antigen.
IPSCIO Record ID: 256328
License Grant
This amendment revises the listed patents. Per the restated agreement, Licensor grants and agrees to grant to Licensee, upon the terms and conditions set forth in this Agreement, the exclusive rights under the Licensed Intellectual Property to make, have made, use and sell Licensed Products and Licensed Processes throughout the world and otherwise to exploit the Licensed Intellectual Property commercially throughout the world.
License Property
With this amendment, the patents are expanded and include Whole Recombinant Yeast Vaccine Activates Dendritic Cells and Elicits Protective Cell-Mediated Immunity, and, Yeast Dendritic Cell Vaccines and Uses Thereof, and, Yeast-Antigen Compositions And Methods Of Making The Same.
Field of Use
Per the restated agreement, the field of use is research and investigation for cancer therapies.
IPSCIO Record ID: 237265
License Grant
Licensor grants to a non-exclusive, sublicensable license to Licensors Intellectual Property in the Territory solely to use and import in the Field nucleic acid sequences encoding for one or more of the Initial Antigens, and to make, have made, use, sell, offer to sell and import Licensees Product(s) in the Field containing a nucleic acid sequence encoding for one or more of the Initial Antigens.
Licensor grants a non-exclusive, sublicensable license to Licensors Intellectual Property in the Territory solely to use and import nucleic acid sequences encoding for such Additional Antigen in the Field, and to make, have made, use, sell, offer to sell and import Licensee Product(s) containing a nucleic acid sequence encoding for such Additional Antigen in the Field.
For the Licensors Applicator and/or Licensors Custom Components, Licensor grants an exclusive, sublicenseable license under the Licensors Patent Rights and Device Custom Know-How to use, sell, offer to sell and import Licensors Applicators and Licensors Custom Components solely for use with a Licensee Product in the Field.
For the Trademark License, Licensor grants a non-exclusive, sublicensable license in the Field in the Territory to use such trademarks and/or trade names Controlled by Licensor, to the extent that such trademarks and/or trade names relate to Licensors Technology, solely in connection with the use, sale, offer to sell and/or import of Licensee Product.
License Property
Licensors Intellectual Property shall mean Licensors Patent Rights and Technology, meaning any and all patents and patent applications in the Territory (which for the purposes of this Agreement shall be deemed to include certificates of invention and applications for certificates of invention) which are Controlled by Licensor during the Term, relating to administration of vaccines by means of or with the assistance of electroporation; or claim or cover Licensors Device Modifications, Licensors Information and Inventions or Joint Information and Inventions; or are divisions, continuations, continuations-in-part, reissues, renewals, extensions, supplementary protection certificates, and the like of any such patents and patent applications, and any foreign equivalents thereof.
Field of Use
The Field shall mean the Licensors Device-assisted delivery of a DNA vaccine for prophylactic and/or therapeutic use in diseases or medical conditions in animals or humans involving hyper plastic and/or hypertrophic cell growth (including oncology) or infectious disease.
A single Indication shall include the primary disease and variants or sub-divisions or sub-classifications within such primary disease. For example, for purposes of the Agreement, breast cancer is a single Indication; treatment of and first line treatment of refractory metastatic breast cancer shall be treated as sub-classifications within the single Indication of breast cancer. Treatment and prophylaxis of the same disease (e.g. breast cancer) shall be treated as the same Indication.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
